Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators..

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

2.

Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice.

Kanematsu S, Yoshizawa K, Uehara N, Miki H, Sasaki T, Kuro M, Lai YC, Kimura A, Yuri T, Tsubura A.

Oncol Rep. 2011 Sep;26(3):603-8. doi: 10.3892/or.2011.1311. Epub 2011 May 20.

PMID:
21617865
3.

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.

Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG.

Am J Nephrol. 2011;33(5):469-76. doi: 10.1159/000327599. Epub 2011 Apr 21.

4.

Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling.

Palsamy P, Subramanian S.

Biochim Biophys Acta. 2011 Jul;1812(7):719-31. doi: 10.1016/j.bbadis.2011.03.008. Epub 2011 Mar 23.

5.

Attenuation of glomerular injury in diabetic mice with tert-butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation.

Li H, Zhang L, Wang F, Shi Y, Ren Y, Liu Q, Cao Y, Duan H.

Am J Nephrol. 2011;33(4):289-97. doi: 10.1159/000324694. Epub 2011 Mar 8.

PMID:
21389693
6.

Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo.

Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T.

Diabetes. 2011 Feb;60(2):625-33. doi: 10.2337/db10-1164.

7.

A glimpse of various pathogenetic mechanisms of diabetic nephropathy.

Kanwar YS, Sun L, Xie P, Liu FY, Chen S.

Annu Rev Pathol. 2011;6:395-423. doi: 10.1146/annurev.pathol.4.110807.092150. Review.

8.

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.

Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8. doi: 10.1073/pnas.1014275108. Epub 2011 Jan 4.

9.

Oxidative stress in early diabetic nephropathy: fueling the fire.

Singh DK, Winocour P, Farrington K.

Nat Rev Endocrinol. 2011 Mar;7(3):176-84. doi: 10.1038/nrendo.2010.212. Epub 2010 Dec 14. Review.

PMID:
21151200
10.

Effects of cinnamaldehyde on the glucose transport activity of GLUT1.

Plaisier C, Cok A, Scott J, Opejin A, Bushhouse KT, Salie MJ, Louters LL.

Biochimie. 2011 Feb;93(2):339-44. doi: 10.1016/j.biochi.2010.10.006. Epub 2010 Oct 16.

11.

Oxidative stress in diabetic nephropathy.

Kashihara N, Haruna Y, Kondeti VK, Kanwar YS.

Curr Med Chem. 2010;17(34):4256-69. Review.

12.

The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells.

Wondrak GT, Villeneuve NF, Lamore SD, Bause AS, Jiang T, Zhang DD.

Molecules. 2010 May 7;15(5):3338-55. doi: 10.3390/molecules15053338.

13.

A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62.

Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, Zhang DD.

Mol Cell Biol. 2010 Jul;30(13):3275-85. doi: 10.1128/MCB.00248-10. Epub 2010 Apr 26.

14.

Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme.

Ping Z, Liu W, Kang Z, Cai J, Wang Q, Cheng N, Wang S, Wang S, Zhang JH, Sun X.

Brain Res. 2010 Jul 9;1343:178-85. doi: 10.1016/j.brainres.2010.04.036. Epub 2010 Apr 24.

PMID:
20417626
15.

The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.

Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD.

Diabetes. 2010 Apr;59(4):850-60. doi: 10.2337/db09-1342. Epub 2010 Jan 26.

16.

Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.

Aleksunes LM, Reisman SA, Yeager RL, Goedken MJ, Klaassen CD.

J Pharmacol Exp Ther. 2010 Apr;333(1):140-51. doi: 10.1124/jpet.109.162271. Epub 2010 Jan 19.

17.

Nrf2 protects against As(III)-induced damage in mouse liver and bladder.

Jiang T, Huang Z, Chan JY, Zhang DD.

Toxicol Appl Pharmacol. 2009 Oct 1;240(1):8-14. doi: 10.1016/j.taap.2009.06.010. Epub 2009 Jun 16.

18.

Differential role of mesangial cells and podocytes in TGF-beta-induced mesangial matrix synthesis in chronic glomerular disease.

Lee HS, Song CY.

Histol Histopathol. 2009 Jul;24(7):901-8. doi: 10.14670/HH-24.901. Review.

PMID:
19475536
19.

Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.

Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, Biswal S.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):250-5. doi: 10.1073/pnas.0804333106. Epub 2008 Dec 22.

20.

Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice.

Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimohata H, Itoh K, Takahashi S, Yamamoto M.

Genes Cells. 2008 Nov;13(11):1159-70. doi: 10.1111/j.1365-2443.2008.01234.x.

Supplemental Content

Support Center